← Back to patent-cliff list
Lanthanum carbonate hydrate
Tier C — Watch / tradeLanthanum carbonate hydrate
Sanofi
Originator
2004
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Phosphates
Brand：Foznol, Fosrenol, Phosbloc, Lambda
Indications (approved)：Hyperphosphataemia
Regional status
US
Approved
2004-10-26
EU
Approved
2004-03-19
China
Approved
2012-02-10
Japan
Approved
2008-10-16
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Lanthanum carbonate hydrate?
Approved indications include: Hyperphosphataemia.
When does the Lanthanum carbonate hydrate patent expire?
No public expiry year is available for Lanthanum carbonate hydrate yet; this page updates once verified.
How do I get a quote for Lanthanum carbonate hydrate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27